Release date: 2018-03-07
March 7th news, according to foreign media reports, the newly established biotechnology company Rubius Therapeutics hopes to use red blood cells instead of missing enzymes, and ultimately effective treatment of some rare, deadly diseases, such as cancer. To date, the company has raised $220 million into research and development.
Just as doctors use the patient's immune system to improve T cells to treat cancer, Rubius Therapeutics is using red blood cells to develop targeted disease therapies. According to media reports, Torben Straight Nissen, executive director of Rubius Therapeutics, believes that their therapy is basically "super blood" because the treatment uses red blood cells instead of chemicals or synthetics. material.
Rubius Therapeutics plans to use medical proteins with red blood cells and adjust them to specific conditions. These special red blood cells are then injected into the patient to begin treatment of the patient's disease. Ultimately, this super blood accounts for less than 1% of the total blood in the patient.
Initially, the company hopes to develop super blood therapy to replace missing enzymes in patients with rare diseases, as well as to treat cancer and autoimmune diseases such as lupus and type 1 diabetes. But unlike T cell therapy, red blood cell therapy has universal applicability. Rubius Therapeutics' website says that we only need a generic donor (a donor with O-type blood) who can produce enough therapeutic doses to treat hundreds to thousands of different patients.
The company is gradually achieving its goals and has recently completed a fundraising of $100 million. In June 2017, the company received $120 million in funding from investors.
In a research report, Nissen pointed out that the increase in funding has further consolidated the company's foundation, enabling us to accelerate the development of the first batch of red blood cell therapy (RCT) products aimed at treating enzyme deficiency, cancer and autoimmune diseases. We have assembled a team of investors, leaders and consultants who have long-term planning and design for patients with novel cell therapy.
It may take a while for Rubius Therapeutics's therapy to be widely used, after all, it is only a concept. First, these therapies must be developed and then validated through a series of clinical trials. If everything goes well, Super Blood will eventually be approved by the US Food and Drug Administration (FDA), just like the 2017 T-cell therapy.
Source: Sina Technology
Nuts Seed Kernel include walnut kernel, sunflower seeds kernel, sunflower seed kernel etc., which are excellent food with rich nutrition.
Seed Kernel,Kernel Fruit,Walnut Kernel,Pumpkin seed kernel, sunflower seed kernel
Xi'an Gawen Biotechnology Co., Ltd , https://www.seoagolyn.com